Biogen Inc (BIIB)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 1,296,400 | 3,679,700 | 1,608,600 | 4,992,900 | 7,046,500 |
| Revenue | US$ in thousands | 9,835,600 | 10,173,400 | 10,981,700 | 13,444,600 | 14,377,900 |
| Pretax margin | 13.18% | 36.17% | 14.65% | 37.14% | 49.01% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $1,296,400K ÷ $9,835,600K
= 13.18%
The pretax margin of Biogen Inc has exhibited fluctuating trends over the past five years. In 2019, the pretax margin was 49.01%, reflecting strong profitability. However, this metric decreased significantly in 2020 to 37.58%, indicating a potential dip in earnings efficiency. The company's performance in 2021 also showed a lower pretax margin of 16.21%, suggesting ongoing challenges in maintaining profitability.
In 2022, the pretax margin rebounded to 35.33%, indicating a recovery in earnings efficiency compared to the previous year. The most recent data for 2023 shows a pretax margin of 13.18%, which is lower relative to the preceding year, indicating a potential dip in profitability.
Overall, the pretax margin of Biogen Inc has shown variability in recent years, with fluctuations possibly reflecting changes in operating costs, sales revenue, or other financial factors affecting the company's earnings performance. Further analysis and consideration of the company's overall financial health and industry trends would be necessary to fully interpret the implications of these fluctuations in pretax margin.
Peer comparison
Dec 31, 2023